Abeona Therapeutics vs Lexicon Pharmaceuticals
ABEO and LXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and LXRX compare
Lexicon Pharmaceuticals is the larger company, worth 5.8 times as much as Abeona Therapeutics ($796M against $138M).
Abeona Therapeutics keeps more of each dollar of sales as profit, with a net margin of −160% compared with −162% at Lexicon Pharmaceuticals.
Abeona Therapeutics scores higher on the StockData Score (8 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | LXRX |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $796M |
| Share price | $2.42 | $1.79 |
| Change, 1 year | −51.0% | 16.2% |
| Change, 5 years | −86.9% | −63.9% |
| Beta (5Y) | 1.30 | 1.76 |
| Employees | 226 | 81 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× (better) | 20.7× |
| P/B | 1.1× (better) | 4.9× |
| FCF yield | −47.9% | – |
| Fair value | $3.99 | $0.871 |
| Margin of safety | 39.4% (better) | −106% |
| Growth | ||
| Revenue growth (TTM) | – | −45.6% |
| Revenue growth, 5Y average | −10.3% | 15.7% (better) |
| Net income growth (TTM) | −176% | – |
| Profitability | ||
| Gross margin | 65.1% | 98.9% (better) |
| Operating margin | −186% | −147% (better) |
| Net margin | −160% (better) | −162% |
| FCF margin | −170% | – |
| Return on equity | −42.1% (better) | −43.9% |
| Return on invested capital | – | −140% |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.32 |
| Interest coverage | −24.5× | – |
| Current ratio | 5.69 | 10.63 (better) |
| Altman Z-score | −4.84 (better) | −5.60 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −8.9% |
| Shareholder yield | 0.00% (better) | −8.9% |
| Ownership | ||
| Held by institutions | 77.9% | 81.9% |
| Held by insiders | 12.3% | – |
| Insider net buying, 12 months | −$3.5M | $2.8M (better) |
| Short interest, % of float | 33.6% | – |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.